S ix million adults in the United States are living with heart failure (HF), with 915 000 cases diagnosed annually. 1 Improvements in medical and device therapy will only increase the number of patients who reach the refractory or advanced HF stage of the disease. In fact, 5% to 25% of all patients with HF are considered to have advanced HF, which is characterized by ongoing symptoms and exceedingly high mortality risk despite guideline-directed medical therapy. 1, 2 Left ventricular assist devices (LVADs) have become an effective therapeutic option to improve survival and quality of life in patients with advanced HF. [3] [4] [5] [6] [7] The majority of LVAD implantations are performed in advanced HF patients who are hospitalized and dependent on inotropic agents, patients with progressive hemodynamic decline, and those in cardiogenic shock. 3 The introduction of continuous-flow technology and newer pump designs has dramatically changed the outlook of end-stage HF, with 1-year survival rates nearing 90% for patients awaiting heart transplantation and 75% for transplant ineligible patients, [3] [4] [5] [6] marked improvement in symptoms, functional capacity, and quality of life. 7
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The success of LVAD therapy has raised interest in implanting LVADs in a broader population of symptomatic, ambulatory advanced HF patients who are not yet inotrope dependent. Such interest is further substantiated by the fact that ambulatory patients with advanced HF have greater survival, shorter length of stay, and lower incidence of severe right ventricular failure. 3, 5, 8 However, before we can expand the indication for an LVAD to this population, a few questions should be be addressed: First, is there equipoise between adverse events and the expected gain in survival and functional capacity? Adverse events related to the use of LVAD technology have decreased over time, [3] [4] [5] [6] with overall rates of 29 events per 100 patient months. However, some of these complications (eg, stroke) can have long-lasting disabling effects, affect transplant candidacy, and increase mortality in these patients. 9, 10 Furthermore, recent reports of an increase incidence of serious complications, including device thrombosis in patients supported by the HeartMate II LVAD 10, 11 and an increased rate of strokes seen in approximately 29% of patients supported by the HeartWare HVAD, have raised significant concerns in the public eye and regulatory agencies. 12 Therefore, additional information on outcomes, adverse events, and quality of life in ambulatory, noninotrope-dependent patients with advanced HF managed medically or with an LVAD is warranted. Ambulatory patients with advanced HF comprise only 20% of the population registered on the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support), and outcomes are limited to the post implantation period. The ROADMAP study (Risk Assessment and Comparative Effectiveness of LVAD and Medical Management) is the first prospective, multicenter, observational study that aimed at providing additional outcome data in ambulatory patients with advanced HF. 13 In that study, 200 ambulatory, noninotrope-dependent patients with advanced HF were enrolled, with 97 patients electing to undergo LVAD implantation and the remaining patients electing to continue medical therapy. The primary composite end point of survival on original therapy with improvement in 6 minute walk distance greater than 75 meters at 12 months occurred more frequently in patients with an LVAD compared with patients on medical therapy (39% versus 21%). Twelve-month survival was also superior in LVAD compared with medical therapy patients (80% versus 63%) in as-treated analysis, although no differences between the groups were observed on intention-to-treat analysis. Improvements in health-related quality of life and depression were also higher in patients who received an LVAD compared with medical therapy, despite higher rates of adverse events (1.89 versus 0.83 events per patient-year) and more frequent hospitalizations. Adverse events in the LVAD group were primarily driven by bleeding (mainly gastrointestinal), and the vast majority of these events were nonfatal and treatable. These data suggest that the balance between expected improvement in survival, functional capacity, and quality of life versus adverse events may be in favor of early LVAD implantation in some patients with ambulatory advanced HF, but the question still remains how to better identify patients more likely to benefit from earlier LVAD implantation?
Many prognostic models and classification schemes, such as the Seattle Heart Failure Model and the New York Heart Association Classification, have been routinely used to derive prognostic information in our patients with HF. However, it is uncertain whether these tools can effectively discriminate INTERMACS Profile in Ambulatory Advanced HF patients within the ambulatory advanced HF population who have significant functional limitations and mortality risk that justifies an earlier LVAD implantation. In addition, some of these schemes are highly subjective, which can lead to patient misclassification. For instance, the New York Heart Association classification system was used in the ROADMAP study as one of the inclusion criteria (i.e. class IIIB). However, it has been widely discussed in the HF scientific and clinical community that this specific system does not include detailed characterization of the various functional classes and therefore can lead clinical investigators to assign variable functional classes in patients with essentially similar clinical characteristics and outcomes. Consequently, such issues make the use of these prognostic models and previous reports difficult to interpret.
In this issue of Circulation: Heart Failure, Stewart et al 14 provide an evaluation of outcomes stratified by baseline INTERMACS profile in ambulatory patients with advanced HF registered in the Medical Arm of Mechanically Assisted Circulatory Support. The primary end point was 1-year risk of death, mechanical circulatory support (MCS), or transplant. Importantly, assessment of health-related quality of life by means of the EuroQOL-5D instrument was conducted in each profile group and compared between medically managed patients registered in Medical Arm of Mechanically Assisted Circulatory Support and LVAD recipients (before implantation) registered in INTERMACS. The Seattle Heart Failure Model score and the HeartMate II Risk Score were calculated for each patient to correlate with INTERMACS profiling and to determine the hypothetical post implant risk if the patients were to require an LVAD. One hundred sixty-six high-risk (80% had 2 hospitalizations in the preceding 12 months) ambulatory, noninotrope-dependent patients with HF, with New York Heart Association class III/IV symptoms, left ventricular ejection fraction ≤30% on maximum tolerated medical therapy were included.
Many relevant observations were made: (1) only 47% of the entire cohort were alive by 1 year, (2) patients in INTERMACS profile 4 were more likely to die or require MCS with only 52% of them alive without support after the first 6 months, (3) 1-year survival in patients with INTERMACS profiles 6 or 7 was similar (84%) to that of LVAD destination therapy patients based on historical data, (4) the Seattle Heart Failure Model underestimates risk for adverse outcomes in this particular group of patients, (5) post-LVAD risk as assessed by HeartMate II Risk Score is low in most ambulatory patients with advanced HF, and (6) health-related quality of life is significantly impaired in ambulatory patients with advanced HF.
What are the implications of these findings? First, these data confirm the results of the ROADMAP study demonstrating poor outcomes in ambulatory patients with advanced HF treated with our standard drug/medical management. Second, it highlights the poor discrimination of routinely used prognostic models in this particular population and more importantly provides support for the use of the INTERMACS profiling as a valuable tool to further risk stratify these patients. In contrast to patients in cardiogenic shock, ambulatory patients with advanced HF have the opportunity and time to choose whether MCS is a reasonable option according to their goals and values. This decision-making process demands from healthcare providers greater knowledge (data driven) and understanding of traditional (eg, survival) and patient-reported outcomes. Patients with an INTERMACS profile 4, as these data suggest, have an increased mortality risk, significant impairments in their health-related quality of life, and functional capacity, which in most cases will move the balance toward the use of MCS. On the other hand, patients with an INTERMACS profile 5 or 6 in whom the survival benefit may be minimal, patientreported outcomes such as quality of life issues and also functional capacity must be carefully taken into consideration.
There are limitations to this work, which need to be considered. First, the number of patients enrolled was relatively small for a subgroup analysis which decreases the power of their findings. Second, as acknowledged by the authors, enrolled patients were not LVAD or transplant candidates, suggesting a different risk profile or set of comorbidities making the extrapolation of these results to our typical patients rather difficult. Third, measures of functional capacity and patientreported outcomes other than health-related quality of life were not assessed in this study. Last, significant heterogeneity exists in the assessment and assignment of the INTERMACS profile, 15 which can affect the evaluated outcomes.
In summary, this study provides evidence that the use of the INTERMACS profiles can be helpful in guiding the decision-making process in ambulatory, noninotrope-dependent advanced HF patients who are being considered for MCS. Although outcomes in medically managed patients with advanced HF support the use of MCS in certain patients (ie, INTERMACS profile 4), further expansion in the use of MCS will require larger, multicenter studies evaluating a wide range of outcomes in ambulatory patients with advanced HF.
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